ArticleJournal of managed care & specialty pharmacy2026
Effect of the initial combination approach vs initial monotherapy approach on 1-year trajectories of adherence in drug-naive patients with type 2 diabetes.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe choice of initial pharmacotherapy approach may influence the medication-taking behavior of patients with type 2 diabetes (T2D). However, there remains a notable gap in the literature to assess the longitudinal adherence pattern of 2 treatment approaches, initial combination vs initial monotherapy with as-needed intensification.
objectiveTo assess the impact of the initial combination therapy approach vs the initial monotherapy approach with as-needed intensification on adherence trajectories and factors associated with the trajectories.
methodsRetrospective study using Merative MarketScan research databases (2017-2019). We have included continuously enrolled drug-naive patients with T2D who received initial monotherapy with as-needed intensification or initial combination therapy. Adherence was measured 12 months after the index date using the proportion of days covered (PDC). Monthly PDC was incorporated into a logistic group-based trajectory model, and patients were categorized into trajectory groups. A multinomial logistic regression model was conducted to examine the association of the diabetes management approach (combination vs initial monotherapy with as-needed intensification) on resultant adherence trajectory, adjusting for baseline characteristics.
resultsWe identified 116,597 Commercial/Medicare and 18,295 patients with Medicaid insurance. The 4-group and 3-group trajectory models for Commercial/Medicare and Medicaid patients, respectively, were selected. Within 1-year follow-up period, odds of lower adherence trajectories were higher for patients receiving initial combination therapy vs initial monotherapy with as-needed intensification group in both populations (Commercial/Medicare; rapid decline: odds ratio [OR] = 1.73, 95% CI = 1.65-1.8; gradual decline: OR = 1.50, 95% CI = 1.41-1.60; gaps in adherence: OR = 1.40, 95% CI = 1.31-1.45; Medicaid; rapid decline trajectory: OR = 1.32, 95% CI = 1.16-1.50).
conclusionsFindings highlighted better adherence patterns among patients receiving initial monotherapy with as-needed intensification compared with initial combination therapy during 1-year post-treatment initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.